166 related articles for article (PubMed ID: 20002082)
21. Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
Tsuchiya S; Friedman E; Addy C; Wakana A; Tatosian D; Matsumoto Y; Suzuki H; Kauh E
J Diabetes Investig; 2017 Jan; 8(1):84-92. PubMed ID: 27182005
[TBL] [Abstract][Full Text] [Related]
22. Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444).
Shon JH; Kim N; Park SJ; Oh MK; Kim EY; Lee SH; Kim YH; Shin JG
Diabetes Obes Metab; 2014 Oct; 16(10):1028-31. PubMed ID: 24641348
[TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetics and pharmacodynamics of PF-00734200, a DPP-IV inhibitor, in healthy Japanese subjects.
Muto C; Dai H; Teeter JG; Johnson S; Cropp AB; Chiba K; Suwa T
Int J Clin Pharmacol Ther; 2012 Jul; 50(7):505-9. PubMed ID: 22541754
[TBL] [Abstract][Full Text] [Related]
24. Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase-4 Inhibitor: A Randomized, Double-Blinded, Placebo-Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus.
Wu M; Li QQ; Zhang H; Zhu XX; Li XJ; Li Y; Sun HG; Ding YH
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):660-668. PubMed ID: 33440080
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.
Rhee SJ; Choi Y; Lee S; Oh J; Kim SJ; Yoon SH; Cho JY; Yu KS
Drug Des Devel Ther; 2016; 10():2525-34. PubMed ID: 27570447
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study.
Yang E; Yoo H; Jang IJ; Yu KS; Lee S
Drug Des Devel Ther; 2021; 15():651-658. PubMed ID: 33628012
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacokinetics and pharmacodynamics of linagliptin.
Graefe-Mody U; Retlich S; Friedrich C
Clin Pharmacokinet; 2012 Jul; 51(7):411-27. PubMed ID: 22568694
[TBL] [Abstract][Full Text] [Related]
29. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
Boulton DW
Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
[TBL] [Abstract][Full Text] [Related]
30. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers.
Hüttner S; Graefe-Mody EU; Withopf B; Ring A; Dugi KA
J Clin Pharmacol; 2008 Oct; 48(10):1171-8. PubMed ID: 18812608
[TBL] [Abstract][Full Text] [Related]
31. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
32. Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats.
Kim Y; Kim U; Kim IS; Lee SH; Lee J; Kim DH; Yoo HH
Xenobiotica; 2014 Jul; 44(7):627-34. PubMed ID: 24738939
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
He YL; Yamaguchi M; Ito H; Terao S; Sekiguchi K
Int J Clin Pharmacol Ther; 2010 Sep; 48(9):582-95. PubMed ID: 20860912
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Shin D; Cho YM; Lee S; Lim KS; Kim JA; Ahn JY; Cho JY; Lee H; Jang IJ; Yu KS
Clin Drug Investig; 2014 Jun; 34(6):383-93. PubMed ID: 24627290
[TBL] [Abstract][Full Text] [Related]
35. A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin.
Lu J; Wang L; Zhou S; Zhou C; Xie L; Chen J; Tang D; Tian X; Xie D; Ding J; Wang T; Yu Q; Ding J; Shao F
Br J Clin Pharmacol; 2022 Jun; 88(6):2946-2958. PubMed ID: 34965609
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
[TBL] [Abstract][Full Text] [Related]
37. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
Dai H; Gustavson SM; Preston GM; Eskra JD; Calle R; Hirshberg B
Diabetes Obes Metab; 2008 Jun; 10(6):506-13. PubMed ID: 18284437
[TBL] [Abstract][Full Text] [Related]
38. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
Kim BH; Lim HS; Chung JY; Kim JR; Lim KS; Sohn DR; Cho JY; Yu KS; Shin SG; Paick JS; Jang IJ
Br J Clin Pharmacol; 2008 Jun; 65(6):848-54. PubMed ID: 18318773
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
Conde-Carmona I; García-Medina S; Jiménez-Vargas JM; Martínez-Muñoz A; Lee SH
Clin Ther; 2018 Oct; 40(10):1729-1740. PubMed ID: 30249366
[TBL] [Abstract][Full Text] [Related]
40. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
